Tag: (NASDAQ:VBIV)

September 10, 2019

VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901

VBI Vaccines (NASDAQ:VBI) has announced a collaboration with GlaxoSmithKline (NYSE:GSK) to evaluate VBI’s VBI-1901 with GSK’s AS01 adjuvant system. As...
May 1, 2019

VBI Vaccines Posts Q1 2019 Financial Results

VBI Vaccines reported its financial results for its Q1 ending March 31, 2019, and offered an update on the progress of...
December 6, 2018

VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences

VBI Vaccines (NASDAQ:VBIV) a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it entered into...
September 25, 2018

VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines (NASDAQ:VBIV) a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the independent Data...
September 9, 2018

5 Top Weekly NASDAQ Biotech Stocks: MannKind Soars 83 Percent

MannKind, Evofem Biosciences, Arbutus Biopharma, Infinity Pharmaceuticals and VBI Vaccines were last week's top gainers on the NASDAQ Biotechnology Index.